摘要
目的评价唑来磷酸(择泰)治疗恶性肿瘤引起高钙血症的有效性和安全性。方法入组患者共有17例,均为校正血钙值>2.7mmol/L的肿瘤患者。以唑来磷酸4mg,静脉滴注15min,观察28d内的校正血钙值。结果本组17例患者均可评价疗效及安全性,有效率为94.1%(16/17),仅1例无效。有效患者的校正血钙均值于用药后第4天第1次复查时即降至正常,于第14天达到最低点,各观察日校正血钙值与疗前比较均明显下降,差异有统计学意义(P均<0.01)。主要不良反应为发热(29.4%,5/17)、低钙性抽搐(11.8%,2/17)和轻度早搏(5.9%,1/17)。结论唑来磷酸治疗恶性肿瘤性高钙血症疗效确切,不良反应轻,耐受性好。
Objective To investigate the effect and safety of zoledronic acid （ Zoledex ）in patients with cancer-induced hypercalcemia. Methods Seventeen patients with cancer-induced hypercalcemia （corrected blood calcium 〉2.70 mmol/L） were treated intravenously by 4 mg zoledex within 15 minutes on the first day. The corrected blood calcium was observed every 4 days in the following 28 days. Results The response rate was 94.1% （16/17）. The mean corrected blood calcium became normal after the first dose of zoledex（ P 〈0.01 ）. The lowest value was found on the fourteenth day after treatment. The main side effects consisted of fever （29.4% ,5/17） , hypocalcemic tetany （ 11.8% , 2/17） and arythmia （5.9% , 1/17）. Conclusion Zoledex is effective and safe in the treatment of patient with cancer-induced hypercalcemia.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2005年第10期632-634,共3页
Chinese Journal of Oncology
关键词
唑来磷酸
肿瘤/治疗
高钙血症
Zoledronic acid
Neoplasm/therapy
Hypercalcemia
